Company Overview

TARSUS PHARMACEUTICALS, INC.

TARS
Revenue vs. Cost of Revenue
Revenue Cost of Revenue
Total Operating Expenses vs. Operating Income
Total Operating Expenses Operating Income
Net Income
Net Income
Revenue
451M
2025 FY
Net Income
-66M
2025 FY
Shares Outstanding
42M
2025 FY
EPS
-1.59USD
2025 FY
Company Information
SIC Code
2836
CIK Code
1819790
Exchange
Nasdaq
Location
US